申请人:Eli Lilly and Company
公开号:US10759786B2
公开(公告)日:2020-09-01
The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
本发明涉及某些新型 2,3-二氢-1H-吲哚化合物、包含这些化合物的药物组合物,以及使用这些化合物治疗癌症的方法,尤其是用于治疗选自黑色素瘤、急性髓细胞白血病、慢性淋巴细胞白血病、结肠直肠癌、乳腺癌、肺癌、卵巢癌、输卵管癌、原发性腹膜癌、宫颈癌、胃癌、肝癌、子宫颈癌、乳腺癌、卵巢癌、输卵管癌、原发性腹膜癌、慢性淋巴细胞白血病、结直肠癌、乳腺癌、肺癌、卵巢癌、输卵管癌、原发性腹膜癌、宫颈癌、胃癌、肝癌、胰腺癌、甲状腺癌、胶质母细胞瘤、非霍奇金淋巴瘤和霍奇金淋巴瘤。